Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer

In a recent OncLive® Scientific Interchange moderated by David R. Gandara, MD, experts discussed the prevalence and pathobiology of SCLC cases in their practices; the role of surgery, radiation, prophylactic cranial irradiation (PCI), and systemic therapy in LS-SCLC; and optimal systemic approaches for ES-SCLC in the first-line and relapsed settings.

Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.